ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CYPB Cypress Bioscience, Inc. (MM)

6.50
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cypress Bioscience, Inc. (MM) NASDAQ:CYPB NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.50 0 01:00:00

- Termination of Registration of a Class of Security under Section 12(g) (15-12G)

14/01/2011 11:01am

Edgar (US Regulatory)


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 000-12943
CYPRESS BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
4350 Executive Drive, Suite 325, San Diego, California 92121
858-452-2323
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $0.001 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
     Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
     
Rule 12g-4(a)(1)
  þ
Rule 12g-4(a)(2)
  o
Rule 12h-3(b)(1)(i)
  þ
Rule 12h-3(b)(1)(ii)
  o
Rule 15d-6
  o
Approximate number of holders of record as of the certification or notice date: One
Pursuant to the requirements of the Securities Exchange Act of 1934, Cypress Bioscience, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
         
     
Date: January 13, 2011  By:   /s/ Pablo Legorreta    
    Name:   Pablo Legorreta   
    Title:   President and Chief Executive Officer   
 
Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.
 
 

1 Year Cypress Bioscience Chart

1 Year Cypress Bioscience Chart

1 Month Cypress Bioscience Chart

1 Month Cypress Bioscience Chart